VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AMSAmerican Shared Hospital Services
$1.64$11M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAMSFinancials

American Shared Hospital Services (AMS) Financials

30Y historyFree accessUpdated daily

Gross margins have experienced a sharp contraction from 49.4% in 2023Q4 to 18.2% in 2026Q1, reflecting significant pressure on the company's core service profitability.

AMS Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue29.05M28.08M28.34M21.32M19.75M17.63M17.84M20.61M19.71M19.56M18.7M16.55M15.42M17.58M17.05M22.22M16.68M16.77M19.1M22.62M20.39M18.23M16.39M16.18M13.37M11.76M9.34M7.16M35.16M37.17M37M
Revenue Growth %-0.62%-0.91%32.9%8%12.02%-1.17%-13.43%4.52%0.81%4.58%13%7.34%-12.32%3.14%-23.28%33.26%-0.55%-12.2%-15.57%10.97%11.82%11.24%1.3%21.04%13.68%25.94%30.46%-79.65%-5.41%0.46%8.5%
Cost of Goods Sold23.67M23.04M19.16M11.98M11.36M10.9M13.37M13.69M12.23M10.89M9.9M9.83M10.14M10.64M10.12M14.22M9.47M9.78M10.88M13.35M4.5M3.68M3.08M3.17M1.93M1.35M1.17M549K20.27M20.65M21.1M
COGS % of Revenue-82.04%67.59%56.18%57.55%61.84%74.96%66.42%62.03%55.7%52.97%59.42%65.76%60.51%59.35%64.01%56.77%58.33%56.95%59.03%22.08%20.17%18.82%19.63%14.42%11.52%12.5%7.67%57.65%55.54%57.03%
Gross Profit5.39M5.04M9.19M9.34M8.38M6.73M4.47M6.92M7.49M8.66M8.79M6.71M5.28M6.94M6.93M8M7.21M6.99M8.22M9.27M15.88M14.55M13.3M13M11.44M10.4M8.17M6.61M14.89M16.53M15.9M
Gross Margin %18.54%17.96%32.41%43.82%42.45%38.16%25.04%33.58%37.97%44.3%47.03%40.58%34.24%39.49%40.65%35.99%43.23%41.67%43.05%40.97%77.92%79.83%81.18%80.37%85.58%88.48%87.5%92.33%42.35%44.46%42.97%
Gross Profit Growth %--45.1%-1.7%11.48%24.62%50.6%-35.46%-7.56%-13.59%-1.5%30.98%27.2%-23.98%0.2%-13.34%10.93%3.18%-15.02%-11.29%-41.66%9.15%9.4%2.31%13.67%9.95%27.36%23.64%-55.63%-9.89%3.94%55.88%
Operating Expenses7.16M7.06M11.99M9.07M5.95M5.38M13.93M4.06M3.99M4.32M3.8M3.5M3.63M4.03M4.04M4.04M4.24M4.27M4.32M6.59M6.16M11.08M10.03M10.03M9.22M6.18M4.92M3.42M10.67M12.3M12.3M
OpEx % of Revenue-25.13%42.31%42.55%30.14%30.49%78.09%19.7%20.26%22.11%20.33%21.13%23.55%22.89%23.73%18.19%25.43%25.47%22.63%29.14%30.2%60.79%61.18%61.98%69%52.53%52.73%47.78%30.35%33.09%33.24%
Selling, General & Admin7.16M7.06M7.41M7.02M5.14M4.53M4.61M4.06M3.99M4.32M3.8M3.5M3.63M4.03M4.04M4.04M4.24M4.27M4.32M4.65M4M3.61M2.96M3.25M3.31M3.25M2.65M1.8M5.12M5.9M5.3M
SG&A % of Revenue-25.13%26.14%32.93%26.06%25.7%25.83%19.7%20.26%22.11%20.33%21.13%23.55%22.89%23.73%18.19%25.43%25.47%22.63%20.54%19.6%19.82%18.08%20.12%24.79%27.6%28.44%25.2%14.55%15.87%14.32%
Research & Development0000000000000000000000000000000
R&D % of Revenue-------------------------------
Other Operating Expenses004.58M2.05M806K844K9.32M003K15K18K28K25K000001.95M2.16M7.47M7.06M6.77M5.91M2.93M2.27M1.62M5.56M6.4M7M
Operating Income-1.77M-2.01M-2.81M270K2.43M1.35M-9.46M-4.54M1.86M2.41M3.29M1.98M-50K1.12M730K1.59M865K653K1.46M2.68M3.86M3.47M3.28M2.98M2.22M4.23M3.25M3.19M4.22M4.23M3.6M
Operating Margin %-6.09%-7.17%-9.9%1.27%12.31%7.66%-53.05%-22.01%9.44%12.34%17.57%11.97%-0.32%6.37%4.28%7.15%5.19%3.89%7.65%11.83%18.96%19.04%20%18.4%16.59%35.96%34.77%44.55%12%11.37%9.73%
Operating Income Growth %-28.2%-1138.89%-88.89%79.94%114.28%-108.67%-343.69%-22.88%-26.57%65.96%4060%-104.46%53.42%-54.06%83.7%32.47%-55.34%-45.37%-30.75%11.32%5.89%10.15%34.24%-47.56%30.25%1.82%-24.45%-0.17%17.42%151.43%
EBITDA3.79M3.7M3.37M5.43M7.55M6.63M-2.49M2.88M8.68M9.09M9.61M8.17M6.33M7.53M6.83M7.86M6.87M7.14M8.18M8.79M9.83M8.97M8.17M7.29M5.75M7.23M5.6M4.81M10.31M10.98M10.6M
EBITDA Margin %13.04%13.18%11.89%25.49%38.24%37.62%-13.98%13.96%44.02%46.48%51.41%49.37%41.08%42.82%40.04%35.38%41.18%42.61%42.81%38.84%48.21%49.22%49.85%45.05%42.99%61.5%60.01%67.2%29.34%29.54%28.65%
EBITDA Growth %39.05%9.82%-38.01%-28.02%13.86%366.02%-186.68%-66.86%-4.52%-5.44%17.66%29.01%-15.9%10.31%-13.17%14.49%-3.9%-12.62%-6.94%-10.58%9.52%9.83%12.09%26.85%-20.54%29.06%16.51%-53.38%-6.05%3.58%488.89%
D&A (Non-Cash Add-back)5.56M5.71M6.17M5.17M5.12M5.28M6.97M7.41M6.82M6.68M6.33M6.19M6.38M6.41M6.1M6.27M6M6.49M6.71M6.11M5.96M5.5M4.89M4.31M3.53M3M2.36M1.62M6.09M6.75M7M
EBIT-1.77M-2.01M2.74M1.81M3.32M1.69M-8.4M2.86M3.49M4.34M4.99M3.22M1.27M2.92M3.08M4.06M3.08M2.78M4.3M2.68M9.73M3.47M3.28M2.98M2.22M4.23M3.25M3.3M4.3M4.23M3.6M
Net Interest Income-1.44M-1.57M-1.25M-686K-719K-742K-1.05M-1.3M-1.43M-1.92M-1.69M-1.22M-1.67M-1.77M-2.1M-2.23M-2M-2M-2.03M-1.62M-1.85M-1.87M-2.16M-2.43M-2.27M-1.98M-1.31M0-3.13M0-4.2M
Interest Income00248K426K87K010K16K198K3K15K18K28K25K58K108K107K60K404K328K308K202K102K121K171K480K804K054K00
Interest Expense1.44M1.57M1.5M1.11M806K742K1.06M1.32M1.63M1.93M1.71M1.24M1.7M1.8M2.15M2.37M2.1M2.06M2.44M1.95M2.16M2.08M2.26M2.55M2.44M2.46M2.12M03.19M04.2M
Other Income/Expense-1.08M-1.21M4.04M426K87K-404K10K16K220K-576K-93K-2.12M-383K-1.15M-1.97M-2.26M107K-2.35M-2.03M-806K-1.01M-924K-881K-807K-660K-2.73M-1.93M-1.3M17.38M-2.69M200K
Pretax Income-2.85M-3.22M1.24M696K2.52M947K-9.45M1.56M2.08M1.84M3.19M-142K-433K-29K920K1.7M972K713K1.01M1.87M2.86M2.55M2.4M2.17M1.56M1.5M1.31M1.99M21.56M1.53M3.8M
Pretax Margin %-9.83%-11.47%4.36%3.26%12.75%5.37%-53%7.56%10.56%9.39%17.07%-0.86%-2.81%-0.16%5.4%7.64%5.83%4.25%5.29%8.27%14.02%13.97%14.63%13.41%11.65%12.77%14.05%27.82%61.33%4.12%10.27%
Income Tax-78K-493K-295K431K963K269K-1.74M128K451K-1.1M943K434K129K84K107K208K166K247K534K919K1.2M780K412K787K455K433K0-716K1.51M10K4M
Effective Tax Rate %2.73%15.31%-23.85%61.93%38.24%28.41%18.38%8.22%21.67%-60.04%29.53%-305.63%-29.79%-289.66%11.63%12.26%17.08%34.64%52.82%49.14%42.06%30.62%17.19%36.28%29.22%28.85%0%-35.96%7.02%0.65%105.26%
Net Income-1.54M-1.55M2.19M610K1.33M194K-7.06M659K1.02M1.92M930K-1.52M-952K-312K38K506K57K-188K477K951K1.66M1.77M1.99M1.38M1.1M1.07M1.31M2.71M20.05M1.52M-400K
Net Margin %-5.3%-5.53%7.71%2.86%6.73%1.1%-39.57%3.2%5.19%9.83%4.97%-9.2%-6.17%-1.77%0.22%2.28%0.34%-1.12%2.5%4.2%8.12%9.69%12.11%8.54%8.24%9.08%14.05%37.83%57.02%4.09%-1.08%
Net Income Growth %-206.8%-171.04%258.36%-54.07%584.54%102.75%-1171.02%-35.58%-46.8%106.77%161.1%-59.87%-205.13%-921.05%-92.49%787.72%130.32%-139.41%-49.84%-42.57%-6.28%-10.98%43.63%25.41%3.18%-18.6%-51.53%-86.5%1217.41%480.5%-105.48%
Net Income (Continuing)-2.78M-2.73M1.53M265K1.55M678K-7.72M1.43M1.63M2.94M2.25M-576K-562K-113K813K1.49M806K466K1.33M951K1.66M1.77M1.99M1.38M1.1M1.07M1.31M2.7M20.1M1.52M-400K
Discontinued Operations0000000000000000000000000000000
Minority Interest3.18M3.66M4.84M3.65M4M4.35M4.38M5.78M5.95M6.03M5.68M5.05M4.73M4.43M4.9M4.97M3.47M3.35M3.21M3.15M3.04M2.53M2.31M1.73M1.45M1.17M1.16M890K731K588K600K
EPS (Diluted)-0.23-0.230.330.100.210.03-1.140.240.170.330.17-0.28-0.19-0.070.010.110.01-0.040.100.190.330.350.390.270.220.210.240.483.150.24-0.08
EPS Growth %-200.84%-169.7%245.91%-54.57%556.25%102.81%-575%41.18%-48.48%94.12%160.71%-47.37%-171.43%-800%-90.91%1000%125%-140%-47.37%-42.42%-5.71%-10.26%44.44%22.73%4.76%-12.5%-50%-84.76%1212.5%400%-104.57%
EPS (Basic)--0.230.340.100.210.03-1.140.240.180.330.17-0.28-0.19-0.070.010.110.01-0.040.100.190.330.360.460.360.300.300.340.684.230.32-0.08
Diluted Shares Outstanding6.72M6.62M6.7M6.39M6.3M6.06M6.18M5.93M6.02M5.83M5.47M5.44M5.01M4.46M4.61M4.62M4.61M4.7M4.99M5.01M5.02M5.05M5.09M4.8M4.85M3.56M3.86M3.97M4.77M6.31M5M
Basic Shares Outstanding6.72M6.62M6.5M6.36M6.3M6.04M6.18M5.92M5.84M5.75M5.47M5.44M5.01M4.46M4.61M4.61M4.6M4.7M4.99M5.01M5.02M4.91M4.32M3.84M3.67M3.56M3.86M3.97M4.75M4.76M5M
Dividend Payout Ratio-------------------75.18%57.61%51.05%35.21%44.14%39.75%33.8%-----

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Operational leverage and utilization

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Volatility Masks Structural Stagnation

According to the provided quarterly income statements, AMS has experienced erratic top-line performance, with revenue fluctuating between $5.2M and $9.1M over the last ten quarters, ultimately failing to establish a consistent growth trajectory despite the recent 15.9% year-over-year increase observed in the 2026Q1 reporting period.

The revenue profile appears highly sensitive to the timing of project-based PBRT installations rather than steady-state procedure growth. Investors should monitor whether the recent uptick in revenue can be sustained or if it merely reflects lumpy, non-recurring project recognition that masks underlying weakness in the legacy Gamma Knife business.

Gross Margin Erosion Signals Pressure

As reported in the company's financial filings, gross margins have experienced a significant contraction, falling from a peak of 49.4% in 2023Q4 to just 18.2% in 2026Q1, reflecting the increasing difficulty of maintaining profitability amidst rising maintenance and equipment service costs.

This sharp decline suggests that the company's fee-per-use model is struggling to absorb inflationary pressures in technical service and parts. The inability to maintain historical margin levels indicates a potential lack of pricing power, which warrants further investigation into the long-term viability of current contract structures.

Operating Leverage Remains Fundamentally Constrained

Based on the income statement data, AMS demonstrates a persistent inability to achieve positive operating leverage, as evidenced by the negative operating margin of -8.8% in 2026Q1, which highlights that corporate overhead continues to outpace the company's ability to scale its clinical partnership revenue.

The high fixed-cost nature of the medical equipment fleet means that even minor fluctuations in procedure volume lead to outsized impacts on operating income. Without a significant increase in fleet utilization, the company appears trapped in a cycle where revenue growth is insufficient to cover the necessary corporate and technical support infrastructure.

Sustainability of Current Business Model

Data from recent quarterly reports suggests that the company's reliance on a capital-intensive, low-margin service model may be unsustainable, as net income has remained negative in four of the last five quarters, raising concerns about the long-term durability of the current clinical partnership strategy.

Short-term observers may focus on the persistent net losses and the potential for future impairment of aging equipment assets. The company's reliance on joint ventures and the associated non-controlling interests complicates the assessment of true economic profitability, suggesting that investors should be cautious regarding the quality of reported earnings.

AMS — Frequently Asked Questions

Quick answers to the most common questions about buying AMS stock.

What was American Shared Hospital Services's (AMS) revenue in 2025?

For fiscal year 2025, American Shared Hospital Services (AMS) reported total revenue of $28.1M. This represents a 24.1% decline compared to $37.0M in 1996.

Is American Shared Hospital Services (AMS) profitable?

American Shared Hospital Services (AMS) reported a net loss of $1.6M for the fiscal year ending 2025.

What is American Shared Hospital Services's operating profit margin?

American Shared Hospital Services (AMS) reported an operating income of $-2.0M, resulting in an operating profit margin of -7.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is American Shared Hospital Services's gross profit and gross margin?

American Shared Hospital Services (AMS) generated $5.0M in gross profit for the year, representing a gross profit margin of 18.0%. This demonstrates the company's core pricing power and production efficiency.